Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data

Martin Schalling(Karolinska University Hospital), Heinz Gisslinger(Medical University of Vienna), Ingrid Simonitsch‐Klupp(Medical University of Vienna), Albert Wölfler(Medical University of Graz), Andreas Gleiß(Medical University of Vienna), Bettina Gisslinger(Medical University of Vienna), Maria‐Theresa Krauth(Medical University of Vienna), Christine Beham‐Schmid(Medical University of Graz), Georg Jeryczynski(Medical University of Vienna), Jürgen Thiele, Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz)
Blood Cancer Journal
December 7, 2017
10.1038/s41408-017-0006-y
Cited by 20

Related Papers

Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)
|Blood|2012|596
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Erythropoietin Treatment of Anemia Associated with Multiple Myeloma
|New England Journal of Medicine|1990|450
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
|Blood|2011|448
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
|The Lancet Haematology|2020|351